Table 4.

ORs and 95% CIs for the risk of postmenopausal breast cancer according to quartiles of prediagnostic biomarkers stratified by BMI (kg/m2)

BMI < 25BMI 25–29.9BMI ≥ 30
Cases/controlsOR (95% CI)aCases/controlsOR (95% CI)aCases/controlsOR (95% CI)aPheterogeneityb
Leptin, ng/mL
 ≤10.4102/1551.0013/181.003/41.00
 10.5–18.996/1131.30 (0.89–1.89)60/531.41 (0.62–3.12)13/101.65 (0.29–9.34)
 19.0–35.167/661.60 (1.03–2.48)104/761.81 (0.82–4.01)45/351.67 (0.34–8.12)
 >35.124/221.72 (0.89–3.32)83/572.10 (0.93–4.77)96/971.30 (0.28–6.08)
Ptrendc0.0360.0660.4880.014
Adiponectin, μg/mL
 ≤5.756/571.0069/681.0057/521.00
 5.8–10.076/711.11 (0.68–1.83)77/581.32 (0.81–2.17)57/471.04 (0.59–1.84)
 10.1–16.162/990.62 (0.38–1.01)74/491.57 (0.93–2.66)22/280.65 (0.32–1.33)
 >16.195/1290.77 (0.48–1.23)40/291.38 (0.73–2.59)21/190.99 (0.44–1.97)
Ptrendc0.1590.3000.6130.164
Leptin:adiponectin
 ≤0.890/1561.0016/171.004/41.00
 0.9–2.2105/1131.65 (1.13–2.40)66/471.60 (0.72–3.54)17/151.31 (0.27–6.35)
 2.3–5.261/591.80 (1.15–2.83)107/771.66 (0.77–3.58)44/421.24 (0.28–5.42)
 >5.233/281.96 (1.10–3.50)71/631.34 (0.61–2.95)92/851.27 (0.30–5.39)
Ptrendc0.0210.7040.9140.011
CRP, mg/L
 ≤0.988/1221.0046/441.0012/111.00
 1.0–1.982/1081.08 (0.72–1.63)59/561.08 (0.61–1.92)34/182.15 (0.76–6.05)
 2.0–4.077/771.49 (0.96–2.32)81/551.56 (0.89–2.73)41/441.06 (0.41–2.74)
 >4.042/491.26 (0.75–2.12)74/491.70 (0.94–3.06)70/731.02 (0.41–2.54)
Ptrendc0.3180.0630.2290.008
  • aORs were obtained from unconditional logistic regression adjusting for age of birth (±1 year), location (HI or CA), ethnicity, date of blood draw (±6 months), time of blood draw (±2 hours), hours fasting before blood draw (<6, 6–<8, 8–<10, ≥10), and hormone replacement therapy use at blood draw (current vs. not current).

  • bP value for the Wald test of Ho: β = 0 for the cross-product terms for continuous variables.

  • cP value for the Wald test of Ho: β = 0 for the natural log-transformed continuous variable.